tldrdailynews.com logo

Sarepta Therapeutics Faces Regulatory and Market Challenges Amid Shipment Pauses and Stock Decline

1 min read
Source: statnews.com
Sarepta Therapeutics Faces Regulatory and Market Challenges Amid Shipment Pauses and Stock Decline
Photo: statnews.com
TL;DR

Sarepta Therapeutics' gene therapy for Duchenne muscular dystrophy, Elevidys, faces significant hurdles to return to the market after safety concerns, including liver injuries linked to patient deaths, making its re-approval challenging and potentially risking license revocation, according to a senior FDA official.

Topics:top-newshealth#duchenne-muscular-dystrophy#elevidys#fda#health#safety-concerns#sarepta-therapeutics
Share this article
  1. Sarepta Therapeutics’ Duchenne therapy faces ‘arduous’ path back to market, senior FDA official says  statnews.com
  2. Sarepta Therapeutics Announces Voluntary Pause of ELEVIDYS Shipments in the U.S.  Sarepta Therapeutics
  3. Drugmaker Refuses F.D.A. Request to Pull Treatment Linked to Patient Deaths  The New York Times
  4. Sarepta to pause gene therapy Elevidys shipments in U.S.  CNBC
  5. Sarepta Stock Is Falling. How Its Crisis Went From Bad to Worse.  Barron's

Want the full story? Read the original reporting

Read on statnews.com